This review discusses our understanding of IDO regulation, highlights mechanisms utilized by cancers to control IDO activity in the tumor immune microenvironment, and outlines pharmacological strategies for reversing these processes to ultimately augment our immunotherapeutic strategies for managing cancer patients. The gene discussed is IDO1; the disease is neoplasm.